Kyntra Bio shares plunge 51% ahead of Q3 earnings and clinical timeline update
KYNB Kyntra Bio Inc
$1.56 -14.75%
View chart & analysis → - 1Kyntra Bio shares fell 51%, compared to a 3% decline in the S&P 500.
- 2Analysts expect a Q3 loss of $3.66 per share and revenue of approximately $2 million.
- 3Kyntra Bio confirmed an interim Phase 2 analysis for metastatic castration-resistant prostate cancer in Q4 2026.
So what's the key point?
Kyntra Bio shares have dropped significantly more than the market. Experts expect a loss of around $3.66 this quarter.
Source Earnings Whispers · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.